ID: ALA4878259

Max Phase: Preclinical

Molecular Formula: C17H13F3N2O2

Molecular Weight: 334.30

Molecule Type: Unknown

Representations

Canonical SMILES:  Cc1ccc(N/N=C(\C(=O)c2ccccc2)C(=O)C(F)(F)F)cc1

Standard InChI:  InChI=1S/C17H13F3N2O2/c1-11-7-9-13(10-8-11)21-22-14(16(24)17(18,19)20)15(23)12-5-3-2-4-6-12/h2-10,21H,1H3/b22-14+

Standard InChI Key:  SWOPDTUTHFESCV-HYARGMPZSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Unknown

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 334.30

Molecular Weight (Monoisotopic): 334.0929

AlogP: 3.78

#Rotatable Bonds: 5

Polar Surface Area: 58.53

Molecular Species: ACID

HBA: 4

HBD: 1

#RO5 Violations: 0

HBA (Lipinski): 4

HBD (Lipinski): 1

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 3.91

CX Basic pKa:

CX LogP: 5.87

CX LogD: 4.14

Aromatic Rings: 2

Heavy Atoms: 24

QED Weighted: 0.39

Np Likeness Score: -1.06

References

1. Makhaeva GF, Lushchekina SV, Boltneva NP, Serebryakova OG, Kovaleva NV, Rudakova EV, Elkina NA, Shchegolkov EV, Burgart YV, Stupina TS, Terentiev AA, Radchenko EV, Palyulin VA, Saloutin VI, Bachurin SO, Richardson RJ..  (2021)  Novel potent bifunctional carboxylesterase inhibitors based on a polyfluoroalkyl-2-imino-1,3-dione scaffold.,  218  [PMID:33831780] [10.1016/j.ejmech.2021.113385]

Source

Source(1):

• Scientific Literature